Al Gore's WST Position Overview
Al Gore (via Generation Investment Management Llp) currently holds 1.56 M shares of West Pharmaceutical Services, Inc. (WST) worth $429.73 M, representing 2.98% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Al Gore has maintained this position in WST for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 585,855 shares. Largest reduction occurred in Q3 2025, reducing 189,763 shares.
Analysis based on 13F filings available since 2013 Q2
Al Gore's West Pharmaceutical Services (WST) Holding Value Over Time
Track share changes against reported price movement
Quarterly West Pharmaceutical Services (WST) Trades by Al Gore
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +585,855 | Add 60.03% | 1.56 M | $275.14 |
| Q3 2025 | -189,763 | Reduce 16.28% | 976,014 | $262.33 |
| Q2 2025 | +1.17 M | New Buy | 1.17 M | $218.80 |
Al Gore's West Pharmaceutical Services Investment FAQs
Al Gore first purchased West Pharmaceutical Services, Inc. (WST) in Q2 2025, acquiring 1,165,777 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Al Gore has held West Pharmaceutical Services, Inc. (WST) for 3 quarters since Q2 2025.
Al Gore's largest addition to West Pharmaceutical Services, Inc. (WST) was in Q2 2025, adding 1,165,777 shares worth $255.07 M.
According to the latest 13F filing for Q4 2025, Al Gore's firm, Generation Investment Management Llp, owns 1,561,869 shares of West Pharmaceutical Services, Inc. (WST), valued at approximately $429.73 M.
As of the Q4 2025 filing, West Pharmaceutical Services, Inc. (WST) represents approximately 2.98% of Al Gore's publicly disclosed stock portfolio, making it one of their key holdings.
Al Gore's peak holding in West Pharmaceutical Services, Inc. (WST) was 1,561,869 shares, as reported at the end of Q4 2025.